Who We Are

Leadgene Biomedical, Inc. develops and manufactures proteins, antibodies, and assay tools as well as offering contracted research services to the diagnostic and pharmaceutical industries.

 

 

Vision

Leadgene Biomedical is dedicated to technological innovation and the creation of visionary products.

Our ambition is to emerge as a leading, groundbreaking, and globally recognized biotech company in Taiwan.

We collaborate with world-renowned experts and partners to build a diverse and competitive team, ensuring alignment with international standards.

Our collective efforts are focused on enhancing human social welfare and generating sustainable value.

 

 

 

Mission

Armed with cutting-edge technology and extensive research and development expertise, Leadgene Biomedical is poised to infuse new energy into Taiwan's biotech sector.

Our mission is to diminish the dependency on imported biological materials, enhance the landscape of Taiwan's biotech industry, and boost its global standing.

As a comprehensive, guidance-driven entity, we boast a complete antibody development technology platform and practical product development capabilities.

Additionally, we provide a range of scientific research products and professional technical systems in immunology and biochemistry.

This strategy seamlessly integrates our research and development strengths with tangible commercial value.

 

  

 

Core Values

Innovation

Leadgene Biomedical independently develops cutting-edge technologies and produces high-quality biological raw material reagents. We offer comprehensive and customized one-stop services for the development of diagnostic reagents. Our company is deeply committed to research and development, consistently investing in R&D to forge unparalleled value. We continually develop products that not only have market potential but also yield significant social benefits. Our robust growth enables us to provide customers with all-encompassing one-stop solutions.

 

Responsibility

Corporate social responsibility is a cornerstone of Leadgene Biomedical's ethos, as we pursue sustainable growth. Beyond profit generation, we are dedicated to the well-being of our employees, society, and the environment. Our goal is to foster a positive social impact while enhancing overall economic benefits. We operate with transparency, openness, efficiency, and regulatory compliance. Our commitment extends to treating our employees with respect, prioritizing their physical and mental health, nurturing strong relationships with customers and downstream suppliers, and proactively addressing customer needs.

 

Sustainability

Leadgene Biomedical is committed to developing products and services that promote technological innovation, forward-thinking, and improved social welfare. We aspire to be a trailblazing, innovative, and international biotech leader in Taiwan. By building a diverse and competitive team of experts and partners globally, we align with international standards and address the critical objectives of Sustainable Development Goals (SDGs). Our determination is to actively engage in environmental protection, social responsibility, and economic development, thereby enhancing human welfare and creating enduring value. 

 

 

 

 

 

 

 

The company was led by a group of young scientists. We provide premium quality reagents through creative and scientific approaches, with production standards outlined in quality management systems ISO 13485, and GMP/QMS guidance. To date, we have built our recognized expertise in technology innovation and will continue to expand these efforts throughout our entire product portfolio.

 

 

 

     
Why choose Leadgene?

Demands from commerce partners always inspire us to improve and innovate. Besides catalog marketing recombinant protein reagents and toolkits, we earn commerce partners’ trust by accomplishing specialized R&D commissions in generating and engineering monoclonal antibodies and cytokines for in vitro diagnostics and clinical studies. Also, we satisfy our customers’ requirements and provide high-quality and valuable customized services, including Biacore analysis, protein identification (tandem mass spectrometry), protein expression and purification.

  • The Invisible Killer - Protein-bound Uremic Toxin Indoxyl Sulfate
  • Leadgene Biomedical, Inc. – Your Trusted Partner in IVD Development
    Leadgene Biomedical, Inc. – Your Trusted Partner in IVD Development
  • Leadgene Protease
    Leadgene Biomedical- Excellence in Recombinant Proteins, Antibodies, and Molecular Biology Solutions
Patents & Publications

Patents

  • Liquid mixing device 2

    • Taiwan 第M537935號 液體混合裝置 2017-03-11 Utility model
    • China ZL 2016 2 1395450.6 液体混合装置 2017-09-08 Utility model
  • Protein delivery tag 1

    • Taiwan 第I609889號 提升蛋白質遞送至細胞內之效率的蛋白標籤及方法 2018-01-01 Invention
  • Anti-indoxyl sulfate monoclonal antibody 5

    • United States US 10,723,791 B2 Compositions of isolated monoclonal antibodies and/or antigen-binding fragments thereof against indoxyl sulfate and uses thereof 2020-07-28 Invention
    • Taiwan 第I710577號 單離抗硫酸吲哚酚之單株抗體及/或其抗原結合片段之組成物暨其使用 2020-11-21 Invention
    • United States US 11,560,423 B2 Isolated monoclonal antibodies and/or antigen-binding fragments thereof against indoxyl sulfate and uses thereof 2023-01-24 Invention
    • Japan 特許第7366353号 抗インドキシル硫酸の単離されたモノクローナル抗体及び/又はその抗原結合断片の組成物及びその用途 2023-10-13 Invention
    • China CN 111741974 B 單離抗硫酸吲哚酚的單株抗體及/或其抗原結合片段的組成物及其使用 2024-01-16 Invention
  • Gastric protein detection method 1

    • Taiwan 第I793238號 體外檢測生物樣品之胃源性蛋白的方法及套組 2023-02-21 Invention

Leadgene Research Highlights

  • 2022 Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model Tien SM, Chang PC, Lai YC, et al. |doi:10.1371/journal.ppat.1010469 PLoS Pathogens
  • 2022 Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan Chao CH, Cheng D, Huang SW, et al. |doi:10.3389/fimmu.2022.1023943 Frontiers in Immunology
  • 2022 Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis Cheng YL, Chao CH, Lai YC, et al. |doi:10.3389/fimmu.2022.941923 Frontiers in Immunology
  • 2022 Antigenic cross-reactivity between SARS-CoV-2 S1-RBD and its receptor ACE2 Lai YC, Cheng YW, Chao CH, et al. |doi:10.3389/fimmu.2022.868724 Frontiers in Immunology
  • 2022 An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection Cheng YW, Chuang YC, Huang SW, et al. |doi:10.1186/s12929-022-00794-2 Journal of Biomedical Science
  • 2021 Rapid SARS-CoV-2 spike protein detection by carbon nanotube-based near-infrared nanosensors Pinals RL, Ledesma F, Yang D, et al. |doi:10.1021/acs.nanolett.1c00118 Nano Letters

Selected Publications

  • 2026 Analytical and clinical validation of a competitive ELISA for serum indoxyl sulfate and its clinical association with chronic kidney disease risk stratification Hou YC, Chuang YC, Cheng YW, et al. |doi:10.1080/0886022X.2026.2679793 Renal Failure
  • 2025 Enhanced sleep quality and reduced indoxyl sulfate levels following probiotic supplementation were linked to gut microbiota modulation in hemodialysis patients Wang YC, Tsai IJ, Hsieh TH, et al. |doi:10.1016/j.jfma.2025.08.036 Journal of the Formosan Medical Association
  • 2025 New biomarkers of inflammation associated with haemodialysis Guerrero F, Carmona A, Jimenez MJ, et al. |doi:10.1093/ckj/sfaf223 Clinical Kidney Journal
  • 2025 Indoxyl sulfate is associated with cognitive impairment in ESRD patients by activating the extrinsic apoptosis in the neuronal cells during differentiating process Hsieh CC, Lu KC, Huang CL, et al. |doi:10.7150/ijms.109245 International Journal of Medical Sciences
  • 2025 The comparison of serum bone-turnover markers in different stage of chronic kidney disease and the associated impact of intradialytic cycling in patients with end-stage renal disease Hou YC, Chao CT, Shih LJ, et al. |doi:10.18632/aging.206177 Aging
  • 2024 Cerebral white matter damage in patients with end-stage kidney disease associates with cognitive impairment Hou YC, Tsai CC, Chen RM, et al. |doi:10.1093/ckj/sfae283 Clinical Kidney Journal
  • 2023 Indoxyl sulfate induced frailty in patients with end-stage renal disease by disrupting the PGC-1a-FNDC5 axis Hou YC, Liao MT, Tsai KW, et al. |doi:10.18632/aging.205141 Aging
  • 2023 Indoxyl sulfate mediates low handgrip strength and is predictive of high hospitalization rates in patients with end-stage renal disease Hou YC, Liu YM, Liao MT, et al. |doi:10.3389/fmed.2023.1023383 Frontiers in Medicine
  • 2022 Assessment of ELISA-based method for the routine examination of serum indoxyl sulfate in patients with chronic kidney disease Duan S, Pi J, Wang CH, et al. |doi:10.1016/j.heliyon.2022.e12220 Heliyon